Merck & Co. Inc. closed 41.34% below its 52-week high of $134.63, which the company achieved on June 25th.

Merck & Company (MRK – Research Report) received a Hold rating and an $85.00 price target from Cantor Fitzgerald analyst Carter Gould ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Omar M. Abuattieh, a student attending the Ernest Mario School of Pharmacy at Rutgers University-New Brunswick, has been ...

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and ...

The stock's rise snapped a three-day losing streak.

President Donald Trump announced a 90-day pause on all tariffs except for those against China, which he said would now rise ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

Shares of some drugmakers rose on Wednesday after President Donald Trump said he would pause steep tariff rates on dozens of ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks 'World Health Day' 2025 in partnership with Africa's First Ladies who ...